Texture analysis versus conventional MRI prognostic factors in predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced cancer of the uterine cervix

2019 ◽  
Vol 124 (10) ◽  
pp. 955-964 ◽  
Author(s):  
Maria Ciolina ◽  
Valeria Vinci ◽  
Laura Villani ◽  
Silvia Gigli ◽  
Matteo Saldari ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Neoadjuvant Chemotherapy ◽  
Texture Analysis ◽  
Advanced Cancer ◽  
Uterine Cervix ◽  
Tumor Response ◽  
Locally Advanced ◽  
Conventional Mri ◽  
Locally Advanced Cancer ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals A retrospective study of prognostic factors in locally advanced cancer of uterine cervix in a Rural Medical College of West Bengal

2014 ◽  
Vol 13 (3) ◽  
pp. 32-35
Author(s):  
Dr. Santanu Acharya ◽  
◽  
Dr. Ashis Kumar Saha ◽  
Dr Bidyut Mandal ◽  
Dr Sumitava De ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retrospective Study ◽  
Advanced Cancer ◽  
Uterine Cervix ◽  
West Bengal ◽  
Locally Advanced ◽  
Medical College ◽  
Locally Advanced Cancer

A pilot study on concurrent platinum chemotherapy and intracavitary brachytherapy for locally advanced cancer of the uterine cervix.

1998 ◽  
Vol 71 (845) ◽  
pp. 552-557 ◽  
Author(s):  
E Koumantakis ◽  
Z Haralambakis ◽  
M Koukourakis ◽  
M Mazonakis ◽  
D Haldeopoulos ◽  
...  
Keyword(s):  
Pilot Study ◽  
Advanced Cancer ◽  
Uterine Cervix ◽  
Locally Advanced ◽  
Intracavitary Brachytherapy ◽  
Platinum Chemotherapy ◽  
Locally Advanced Cancer

Biomarkers detected by proteomic analysis predicts breast cancer response to neoadjuvant chemotherapy

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 669-669
Author(s):  
D. Shen ◽  
J. He ◽  
J. Gornbein ◽  
Z. Chen ◽  
K. F. Faull ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Proteomic Analysis ◽  
Tumor Response ◽  
Classification Tree ◽  
Objective Assessment ◽  
Locally Advanced ◽  
Poor Responders ◽  
Protein Biomarkers ◽  
Response To Neoadjuvant Chemotherapy

669 Background: Neoadjuvant chemotherapy provides an excellent opportunity for objective assessment of treatment-induced tumor response and for studying biomarkers characteristic of therapy-induced tumor responses. Methods: Proteomic analysis of T3/T4 breast cancer was performed in patients with locally advanced breast cancer in a phase II clinical trial. The breast cancer specimen was obtained before and after four cycles of Taxotere/Carboplatin/±Herceptin treatment. Two proteomic approaches, SELDI mass spectrometry and Clontech Ab Microarray 500, were used to screen for protein biomarkers that predict response of breast cancer to chemotherapy. Results: Five tumors with pathologically complete response (pCR) and 29 tumors with various amounts of residual tumors (Non-pCR) were analyzed by SELDI-TOF using the NP 20 chip. The normalized mass signals were compared between pCR vs Non-pCR at each aligned location by Wilcoxon rank sum test. Statistically significant differences were found at 22 m/z locations using a liberal p <0.20 criterion. The best univariate predictor occurred at m/z 14960 (p=0.004), which correctly classified 5/5 pCR spectra (100%) and 24/29 Non-pCR spectra (83%). A multivariate classification tree developed using m/z 14960 and m/z 12138 intensities correctly classified all 34 spectra. Ab microarray analysis was performed on five pCR tumors and in five tumors with the largest residual cancer. The Internal Normalization Ratio (INR) was calculated and used to compare the difference of protein expression between the two groups. Eight differentially expressed protein biomarkers were selected with the criteria of a statistically significant (Student t, p<0.05) expression change of <0.77 or >1.3 fold. Three proteins (Tat-SF1, PYK2 and PTP1B) were higher, and five (E2F2, IL1b, FEN1, CDC37 and ACM1) were lower in tumors with pCR. The unsupervised hierarchical clustering of the 10 samples by these eight proteins completely separated the pCR tumors from the poor responders. Conclusions: Our study suggests that bothSELDImass spectrometry and antibody microarray may be used to predict the tumor response to neoadjuvant chemotherapy. Proteomic analysis may be useful in developing tailored chemotherapy for breast cancer. [Table: see text]

scholarly journals 99mTc-sestamibi scintigraphy used to evaluate tumor response to neoadjuvant chemotherapy in locally advanced breast cancer: A quantitative analysis

2010 ◽  
Vol 1 (2) ◽  
pp. 379-382 ◽  
Author(s):  
KATIA HIROMOTO KOGA ◽  
SONIA MARTA MORIGUCHI ◽  
JORGE NAHÁS NETO ◽  
STELA VERZINHASSE PERES ◽  
EDUARDO TINÓIS DA SILVA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantitative Analysis ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Tumor Response ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
99Mtc Sestamibi ◽  
Response To Neoadjuvant Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document